| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (NCT05189457) | H. Lee Moffitt Cancer Center and Research Institute | 2022-01-25 |
| Ask Questions (ASQ):Implementation of a Communication Intervention (NCT05025748) | Barbara Ann Karmanos Cancer Institute | 2021-08-25 |
| Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites (NCT04267575) | Jerome Canady, M.D. | 2019-07-30 |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03805594) | University of California, San Francisco | 2019-05-10 |
| Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer (NCT03880422) | Roswell Park Cancer Institute | 2019-05-02 |
| Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (NCT03827473) | University of Utah | 2019-02-08 |
| Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer (NCT03477864) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-12-24 |
| Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer (NCT03344211) | University of Southern California | 2018-11-21 |
| Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer (NCT04113096) | The University of The West Indies | 2018-10-01 |
| Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (NCT03511196) | H. Lee Moffitt Cancer Center and Research Institute | 2018-09-17 |
| Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy (NCT03596710) | Jonsson Comprehensive Cancer Center | 2018-06-14 |
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer (NCT02881242) | Jonsson Comprehensive Cancer Center | 2018-01-30 |
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners (NCT03112668) | Rutgers, The State University of New Jersey | 2017-12-06 |
| Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer (NCT03016741) | Northwestern University | 2017-03-31 |
| Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer (NCT02935205) | Mamta Parikh | 2017-01-17 |
| Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects (NCT03012321) | Northwestern University | 2017-01-12 |
| Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer (NCT03123978) | University of California, Davis | 2017-01-09 |
| Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (NCT02807805) | Mamta Parikh | 2016-10-01 |
| Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer (NCT02516670) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-06-20 |
| Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway (NCT02598895) | University of Washington | 2016-01-26 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319) | Mayo Clinic | 2016-01-01 |
| Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer (NCT02489357) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-11 |
| Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer (NCT02169063) | University of Washington | 2015-12-01 |
| Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (NCT02278185) | University of Colorado, Denver | 2015-11-11 |
| Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer (NCT02615223) | Tianjin Medical University Cancer Institute and Hospital | 2015-11-01 |
| Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (NCT02491411) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-09-01 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer (NCT02499835) | University of Wisconsin, Madison | 2015-07-01 |
| Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery (NCT02144649) | Ohio State University Comprehensive Cancer Center | 2015-06-01 |
| Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer (NCT02048150) | City of Hope Medical Center | 2015-03-13 |
| Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT02159950) | Roswell Park Cancer Institute | 2015-01-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer (NCT02206334) | NRG Oncology | 2014-08-01 |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer (NCT02184533) | Stanford University | 2014-07-01 |
| LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (NCT02058706) | Barbara Ann Karmanos Cancer Institute | 2014-05-01 |
| Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer (NCT01949337) | Alliance for Clinical Trials in Oncology | 2014-01-22 |
| Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery (NCT01912820) | Jonsson Comprehensive Cancer Center | 2014-01-01 |
| Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer (NCT02012296) | University of Chicago | 2013-12-13 |
| Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01866423) | University of Southern California | 2013-10-25 |
| CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01881867) | Fred Hutchinson Cancer Center | 2013-09-10 |
| Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (NCT01848067) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-08-14 |
| Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery (NCT02603965) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-08-01 |
| Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T (NCT01833208) | Roswell Park Cancer Institute | 2013-07-03 |
| Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01913015) | OHSU Knight Cancer Institute | 2013-07-01 |
| Cabozantinib in Men With Castration-Resistant Prostate Cancer (NCT01703065) | University of Washington | 2013-06-18 |
| Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (NCT01807065) | City of Hope Medical Center | 2013-06-07 |
| Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy (NCT02050906) | Ohio State University Comprehensive Cancer Center | 2013-05-21 |
| Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer (NCT01731912) | University of Washington | 2013-05-01 |
| Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide (NCT02228265) | OHSU Knight Cancer Institute | 2013-03-12 |
| Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (NCT01812668) | Barbara Ann Karmanos Cancer Institute | 2013-03-01 |
| Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01685125) | University of Southern California | 2012-09-01 |
| Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel (NCT01469338) | University of Southern California | 2012-07-01 |
| Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer (NCT01599793) | University of Chicago | 2012-05-01 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy (NCT01555632) | University of Nebraska | 2012-03-01 |
| Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01498978) | OHSU Knight Cancer Institute | 2012-02-06 |
| Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer (NCT01533246) | National Cancer Institute (NCI) | 2012-02-01 |
| Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer (NCT01174199) | Roswell Park Cancer Institute | 2012-02-01 |
| Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer (NCT01385059) | City of Hope Medical Center | 2011-10-28 |
| Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01468532) | Barbara Ann Karmanos Cancer Institute | 2011-10-01 |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (NCT01120236) | National Cancer Institute (NCI) | 2010-12-01 |
| Saracatinib in Treating Patients With Prostate Cancer (NCT01267266) | National Cancer Institute (NCI) | 2010-12-01 |
| Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01240629) | University of Southern California | 2010-11-02 |
| Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer (NCT01200810) | National Cancer Institute (NCI) | 2010-08-01 |
| Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01145508) | National Cancer Institute (NCI) | 2010-08-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer (NCT01117935) | Virginia Commonwealth University | 2010-05-30 |
| Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer (NCT01023061) | University of Washington | 2010-03-01 |
| Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer (NCT00956163) | National Cancer Institute (NCI) | 2010-03-01 |
| Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer (NCT01050842) | Mayo Clinic | 2010-02-01 |
| Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen (NCT01682941) | Ohio State University Comprehensive Cancer Center | 2009-10-01 |
| Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases (NCT00936975) | National Cancer Institute (NCI) | 2009-09-01 |
| Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients (NCT00879619) | John P. Fruehauf | 2009-07-01 |
| R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (NCT00666666) | National Cancer Institute (NCI) | 2009-07-01 |
| Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy (NCT00937768) | Mayo Clinic | 2009-07-01 |
| Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00527124) | National Cancer Institute (NCI) | 2007-11-01 |
| Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00337077) | National Cancer Institute (NCI) | 2006-11-01 |
| Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer (NCT00536991) | Roswell Park Cancer Institute | 2006-10-01 |
| Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy (NCT00331344) | National Cancer Institute (NCI) | 2006-04-01 |
| Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer (NCT00330161) | National Cancer Institute (NCI) | 2006-03-01 |
| Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00110214) | National Cancer Institute (NCI) | 2005-04-01 |
| SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel (NCT00096499) | National Cancer Institute (NCI) | 2005-04-01 |
| 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy (NCT00118092) | National Cancer Institute (NCI) | 2005-01-01 |
| Cilengitide in Treating Patients With Metastatic Prostate Cancer (NCT00103337) | National Cancer Institute (NCI) | 2005-01-01 |
| Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer (NCT00095667) | National Cancer Institute (NCI) | 2004-11-01 |
| Ixabepilone in Treating Patients With Metastatic Prostate Cancer (NCT00087139) | National Cancer Institute (NCI) | 2004-09-01 |
| Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer (NCT00170157) | Mayo Clinic | 2004-06-01 |
| Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer (NCT00058084) | National Cancer Institute (NCI) | 2003-03-01 |
| Perifosine in Treating Patients With Recurrent Prostate Cancer (NCT00058214) | National Cancer Institute (NCI) | 2003-03-01 |
| Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT00058253) | National Cancer Institute (NCI) | 2003-02-01 |
| BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy (NCT00040755) | National Cancer Institute (NCI) | 2002-05-01 |
| Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer (NCT00039104) | National Cancer Institute (NCI) | 2002-04-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer (NCT00016107) | National Cancer Institute (NCI) | 2001-06-01 |
| Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) (NCT00005039) | National Cancer Institute (NCI) | 2000-01-01 |
| Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer (NCT00020046) | National Institutes of Health Clinical Center (CC) | 1999-12-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer (NCT00019695) | National Cancer Institute (NCI) | 1999-03-01 |
| Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer (NCT00003534) | Burzynski Research Institute | 1996-10-11 |
| Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer (NCT00003517) | Burzynski Research Institute | |